Genomma Lab: Q2 Sales Down 3.6%, Market Share Holds
Genomma Lab Internacional reported a 3.6% decline in like-for-like sales for Q2 2026, citing market softness. Net income increased by 5.5%, and the company maintained or grew market share.
Genomma Lab Internacional announced its second-quarter 2026 financial results, revealing a 3.6% decrease in like-for-like sales. The company attributed the decline to ongoing market softness, particularly in the US Hispanic market, though it noted a 3.9% increase in sales in Latin America.
Despite the overall sales dip, Genomma Lab stated that its market share remained stable or increased across all business units. In Mexico, "sell-in" sales fell 4.4% and "sell-out" fell 4.0%. However, the company indicated that "sell-out" sales turned positive in early July, driven by the launch of new products like Suerox Mineral.
The company's gross margin improved by 106 basis points to 64.6%, a result of productivity gains that outweighed increased promotional investments. EBITDA margin was 21.8%, in line with expectations. Net income saw a 5.5% rise, attributed to lower financial expenses and reduced foreign exchange losses.
Genomma Lab anticipates a gradual recovery through the second half of 2026, focusing on growth initiatives, market share defense, and cost discipline. The company plans to host an earnings call on July 23, 2026, to discuss these results. Genomma Lab's shares are listed on the Mexican Stock Exchange.